CA2472920A1 - Methods of reducing angiogenesis - Google Patents
Methods of reducing angiogenesis Download PDFInfo
- Publication number
- CA2472920A1 CA2472920A1 CA002472920A CA2472920A CA2472920A1 CA 2472920 A1 CA2472920 A1 CA 2472920A1 CA 002472920 A CA002472920 A CA 002472920A CA 2472920 A CA2472920 A CA 2472920A CA 2472920 A1 CA2472920 A1 CA 2472920A1
- Authority
- CA
- Canada
- Prior art keywords
- mammal
- administering
- tumor
- angiogenesis
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
Claims (14)
- A method of reducing angiogenesis in a mammal, the method comprising administering to a mammal a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce angiogenesis.
- 2. The method of claim 1, wherein the nAChR antagonist is selected from the group consisting of mecamylamine; hexamethonium, dihydro-beta-erythroidine, d-tubocurarine, pempidine, chlorisondamine, erysodine, trimethaphan camsylate, pentolinium, bungarotoxin, succinylcholine, tetraethylammonium, trimethaphan, chlorisondamine, and trimethidinium.
- 3. The method of claim l, wherein said administering is by a route selected from the group consisting of intravenous, in or around a solid tumor, systemic, intraarterial, and topical.
- 4. A method of treating a disorder associated with pathological angiogenesis, the method comprising administering to a mammal a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce pathological angiogenesis.
- 5. The method of claim 4, wherein the nAChR antagonist is selected from the group consisting of mecamylamine; hexamethonium, dihydro-beta-erythroidine, d-tubocurarine, pempidine, chlorisondamine, erysodine, trimethaphan camsylate, pentolinium, bungarotoxin, succinylcholine, tetraethylammonium, trimethaphan, chlorisondamine, and trimethidinium.
- 6. The method of claim 4, wherein said administering is by a route selected from the group consisting of intravenous, in or around a solid tumor, systemic, intraarterial, and topical.
- 7. The method of claim 4, further comprising administering a second angiogenesis inhibitor.
- 8. A method of inhibiting tumor growth in a mammal, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce angiogenesis, wherein said administering is peritumoral, and wherein a reduction in angiogenesis inhibits tumor growth.
- 9. The method according to claim 8, further comprising administering an anti-tumor chemotherapeutic agent.
- 10. A method of inhibiting abnormal fibrovascular growth in a mammal, the method comprising administering to a mammal having abnormal fibrovascular growth a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce abnormal fibrovascular growth in the mammal.
- 11. The method of claim 10, wherein the abnormal fibrovascular growth is associated with inflammatory arthritis.
- 12. A method of inhibiting a proliferative retinopathy in a mammal, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce the proliferative retinopathy in the mammal.
- 13. The method according claim 12, wherein the proliferative retinopathy occurs as a result of diabetes in the mammal.
- 14. A method of inhibiting pathological neovascularization associated with a tumor, the method comprising administering to a mammal having a tumor a nicotinic acetylcholine receptor (nAChR) antagonist in an amount effective to reduce the tumor-associated pathological neovascularization in the mammal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35668702P | 2002-02-12 | 2002-02-12 | |
US60/356,687 | 2002-02-12 | ||
PCT/US2003/003294 WO2003068208A1 (en) | 2002-02-12 | 2003-02-04 | Methods of reducing angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2472920A1 true CA2472920A1 (en) | 2003-08-21 |
CA2472920C CA2472920C (en) | 2012-08-21 |
Family
ID=27734668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2472920A Expired - Fee Related CA2472920C (en) | 2002-02-12 | 2003-02-04 | Methods of reducing angiogenesis |
Country Status (10)
Country | Link |
---|---|
US (3) | US7045534B2 (en) |
EP (1) | EP1480627B1 (en) |
JP (2) | JP4494793B2 (en) |
AT (1) | ATE478661T1 (en) |
AU (1) | AU2003214991B2 (en) |
CA (1) | CA2472920C (en) |
DE (1) | DE60333901D1 (en) |
DK (1) | DK1480627T3 (en) |
ES (1) | ES2349244T3 (en) |
WO (1) | WO2003068208A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
DE102004016179A1 (en) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Compounds for the treatment of proliferative processes |
US20060188508A1 (en) * | 2005-02-17 | 2006-08-24 | Cohen Stanley N | Methods and compositions for modulating angiogenesis |
US20080275134A1 (en) * | 2005-02-24 | 2008-11-06 | University Of Washington | Methods for Treatment of Retinal Degenerative Disease |
US20070123448A1 (en) * | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
EP1978926A2 (en) * | 2005-12-19 | 2008-10-15 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses thereof |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
DK2087001T3 (en) * | 2006-11-02 | 2017-02-06 | Acceleron Pharma Inc | ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND APPLICATIONS THEREOF |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
CL2008003507A1 (en) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system. |
KR20190128254A (en) | 2008-05-02 | 2019-11-15 | 악셀레론 파마 인코포레이티드 | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage |
WO2009140201A1 (en) * | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
WO2010056622A1 (en) * | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
WO2011047341A2 (en) | 2009-10-16 | 2011-04-21 | University Of South Florida | Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors |
JP2011184344A (en) * | 2010-03-08 | 2011-09-22 | Kao Corp | p21 EXPRESSION PROMOTER |
WO2012106812A1 (en) * | 2011-02-08 | 2012-08-16 | Mcmaster University | A method of treating cancer |
CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
KR20160061911A (en) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | Therapeutic benefit of suboptimally administered chemical compounds |
KR101921259B1 (en) | 2017-03-02 | 2018-11-22 | 전남대학교산학협력단 | Pharmaceutical composition for the prevention of kidney disease |
CN112237631B (en) * | 2019-07-16 | 2022-03-04 | 清华大学 | Use of acetylcholine pathway modulators in the treatment of cancer |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686448A (en) * | 1983-01-10 | 1997-11-11 | Baltech, Inc. | Treatment of virus infections with ganglionic blocking agents |
US4503038A (en) * | 1983-02-25 | 1985-03-05 | The Regents Of The University Of California | Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid |
US4966890A (en) * | 1986-04-04 | 1990-10-30 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
BR9509985A (en) * | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solution for irrigation and method for inhibiting pain, inflammation and sparse |
US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
US6034079A (en) * | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
TW432397B (en) * | 1997-10-23 | 2001-05-01 | Sumitomo Metal Mining Co | Transparent electro-conductive structure, progess for its production, transparent electro-conductive layer forming coating fluid used for its production, and process for preparing the coating fluid |
WO1999062505A2 (en) * | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
US6121289A (en) * | 1998-10-09 | 2000-09-19 | Theramax, Inc. | Method for enhanced brain delivery of nicotinic antagonist |
US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US7973068B2 (en) * | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
EP1139743B1 (en) | 1998-12-16 | 2006-03-22 | University Of South Florida | Exo-s-mecamylamine formulation and use in treatment |
US6734215B2 (en) * | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
US6472379B1 (en) | 1999-03-15 | 2002-10-29 | Trustees Of Boston University | Angiogenesis inhibition |
CA2380072C (en) | 1999-07-28 | 2007-07-10 | John Cooke | Nicotine in therapeutic angiogenesis and vasculogenesis |
US6337076B1 (en) * | 1999-11-17 | 2002-01-08 | Sg Licensing Corporation | Method and composition for the treatment of scars |
US20030096831A1 (en) | 2000-01-18 | 2003-05-22 | Stone Richard A. | Ocular growth and nicotinic antagonists |
US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
US20030158112A1 (en) * | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
CN1735414A (en) * | 2002-12-06 | 2006-02-15 | 北岸长岛犹太人研究学院 | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US20050075702A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
-
2003
- 2003-02-03 US US10/358,370 patent/US7045534B2/en not_active Expired - Fee Related
- 2003-02-04 DE DE60333901T patent/DE60333901D1/en not_active Expired - Lifetime
- 2003-02-04 AU AU2003214991A patent/AU2003214991B2/en not_active Ceased
- 2003-02-04 ES ES03710841T patent/ES2349244T3/en not_active Expired - Lifetime
- 2003-02-04 JP JP2003567390A patent/JP4494793B2/en not_active Expired - Fee Related
- 2003-02-04 AT AT03710841T patent/ATE478661T1/en active
- 2003-02-04 DK DK03710841.2T patent/DK1480627T3/en active
- 2003-02-04 EP EP03710841A patent/EP1480627B1/en not_active Expired - Lifetime
- 2003-02-04 CA CA2472920A patent/CA2472920C/en not_active Expired - Fee Related
- 2003-02-04 WO PCT/US2003/003294 patent/WO2003068208A1/en active IP Right Grant
-
2006
- 2006-03-01 US US11/366,163 patent/US7390821B2/en not_active Expired - Fee Related
-
2008
- 2008-05-09 US US12/118,373 patent/US7652038B2/en not_active Expired - Fee Related
-
2010
- 2010-01-19 JP JP2010008618A patent/JP2010143935A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7652038B2 (en) | 2010-01-26 |
AU2003214991B2 (en) | 2007-06-21 |
EP1480627A1 (en) | 2004-12-01 |
US7390821B2 (en) | 2008-06-24 |
JP2005521683A (en) | 2005-07-21 |
US7045534B2 (en) | 2006-05-16 |
EP1480627A4 (en) | 2005-04-06 |
AU2003214991A1 (en) | 2003-09-04 |
DK1480627T3 (en) | 2010-11-08 |
ES2349244T3 (en) | 2010-12-29 |
DE60333901D1 (en) | 2010-10-07 |
JP2010143935A (en) | 2010-07-01 |
EP1480627B1 (en) | 2010-08-25 |
ATE478661T1 (en) | 2010-09-15 |
US20080242591A1 (en) | 2008-10-02 |
CA2472920C (en) | 2012-08-21 |
WO2003068208A1 (en) | 2003-08-21 |
US20060148675A1 (en) | 2006-07-06 |
JP4494793B2 (en) | 2010-06-30 |
US20030216314A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2472920A1 (en) | Methods of reducing angiogenesis | |
WO2008093148A3 (en) | Compositions and methods for prevention and treatment of cachexia | |
PT979329E (en) | A METAL NETWORK FOR PROVIDING A PROTECTION AGAINST STONE FALL OR TO CONSOLIDATE A SURFACE LAND LAYER AS WELL AS A PROCESS AND A DEVICE FOR THE MANUFACTURE OF THAT NETWORK | |
KR20180131943A (en) | Steel sheet for hot press formed member having excellent coating adhesion and manufacturing method for the same | |
KR100711469B1 (en) | A method for manufacturing 2000mpa grade hypereutectoid steel wire | |
KR101331975B1 (en) | Composition having a corrosion protection layer and process for producing it | |
DE102004063816B3 (en) | Cutting plate for a cutting tool comprises a wear-reducing coating consisting of a multiple layer base layer, an aluminum oxide multiple layer and a two-layer covering layer | |
CN104967059A (en) | Hull navigation bridge cable laying method | |
WO2011065206A1 (en) | Wave absorbing device | |
KR101568499B1 (en) | High strength wire, wire rod therefor and manufacturing method of haigh strength wire | |
JP2016121432A (en) | Thick wire net and net weaving method for the same | |
DE10310842A1 (en) | Electronic component with semiconductor chip and plastic housing and method for producing the same | |
KR101549660B1 (en) | Overhead Conductor using Ultra High Strength Steel Wire | |
JP4885101B2 (en) | Construction method of concrete embankment | |
KR101518602B1 (en) | Method for manufacturing high-strength drawn wire having excellent twist property | |
KR102147701B1 (en) | Manufacturing method of high carbon steel wire having excellent torsional characteristics and strength | |
KR101758477B1 (en) | High carbon stell wire rod and steel wire having excellent strength and corrosion resistance and method for manufacturing thereof | |
CA2017846A1 (en) | Rod elevator insert | |
JP2011140858A (en) | Concrete column excelling in durability | |
JP2011226138A (en) | Concrete column excellent in durability | |
DE10316153B4 (en) | Arrangement for limiting condensation on beam heads of a building | |
WO2017111467A1 (en) | Austenitic stainless steel having improved processability | |
WO2011145856A2 (en) | Wire tool | |
AU2014100218A4 (en) | Method for improving the corrosion resistance of stainless steel mesh used to protect buildings from concealed termite entry | |
KR101328338B1 (en) | Wire rod and heat treated wire rod for drawing and high strength stell wire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170206 |